Literature DB >> 30049452

Generation of Hepatic Stellate Cells from Human Pluripotent Stem Cells Enables In Vitro Modeling of Liver Fibrosis.

Mar Coll1, Luis Perea2, Ruben Boon3, Sofia B Leite4, Julia Vallverdú2, Inge Mannaerts4, Ayla Smout4, Adil El Taghdouini4, Delia Blaya2, Daniel Rodrigo-Torres2, Isabel Graupera5, Beatriz Aguilar-Bravo2, Christophe Chesne6, Mustapha Najimi7, Etienne Sokal7, Juan José Lozano8, Leo A van Grunsven9, Catherine M Verfaillie10, Pau Sancho-Bru11.   

Abstract

The development of complex in vitro hepatic systems and artificial liver devices has been hampered by the lack of reliable sources for relevant cell types, such as hepatic stellate cells (HSCs). Here we report efficient differentiation of human pluripotent stem cells into HSC-like cells (iPSC-HSCs). iPSC-HSCs closely resemble primary human HSCs at the transcriptional, cellular, and functional levels and possess a gene expression profile intermediate between that of quiescent and activated HSCs. Functional analyses revealed that iPSC-HSCs accumulate retinyl esters in lipid droplets and are activated in response to mediators of wound healing, similar to their in vivo counterparts. When maintained as 3D spheroids with HepaRG hepatocytes, iPSC-HSCs exhibit a quiescent phenotype but mount a fibrogenic response and secrete pro-collagen in response to known stimuli and hepatocyte toxicity. Thus, this protocol provides a robust in vitro system for studying HSC development, modeling liver fibrosis, and drug toxicity screening.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  differentiation; disease modeling; hepatic stellate cells; in vitro liver model; liver fibrosis; liver spheroids; non-parenchymal cells; organoids; pluripotent stem cells; toxicity assessment

Mesh:

Substances:

Year:  2018        PMID: 30049452     DOI: 10.1016/j.stem.2018.05.027

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  50 in total

1.  Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.

Authors:  Rie Ouchi; Shodai Togo; Masaki Kimura; Tadahiro Shinozawa; Masaru Koido; Hiroyuki Koike; Wendy Thompson; Rebekah A Karns; Christopher N Mayhew; Patrick S McGrath; Heather A McCauley; Ran-Ran Zhang; Kyle Lewis; Shoyo Hakozaki; Autumn Ferguson; Norikazu Saiki; Yosuke Yoneyama; Ichiro Takeuchi; Yo Mabuchi; Chihiro Akazawa; Hiroshi Y Yoshikawa; James M Wells; Takanori Takebe
Journal:  Cell Metab       Date:  2019-05-30       Impact factor: 27.287

2.  The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway.

Authors:  Siwei Tan; Huiling Liu; Bilun Ke; Jie Jiang; Bin Wu
Journal:  Br J Pharmacol       Date:  2020-03-03       Impact factor: 8.739

Review 3.  Gaining New Biological and Therapeutic Applications into the Liver with 3D In Vitro Liver Models.

Authors:  Sang Woo Lee; Da Jung Jung; Gi Seok Jeong
Journal:  Tissue Eng Regen Med       Date:  2020-03-23       Impact factor: 4.169

Review 4.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

Review 5.  Challenges and Opportunities in the Design of Liver-on-Chip Microdevices.

Authors:  Avner Ehrlich; Daniel Duche; Gladys Ouedraogo; Yaakov Nahmias
Journal:  Annu Rev Biomed Eng       Date:  2019-06-04       Impact factor: 9.590

6.  Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism.

Authors:  Alexandra Collin de l'Hortet; Kazuki Takeishi; Jorge Guzman-Lepe; Kazutoyo Morita; Abhinav Achreja; Branimir Popovic; Yang Wang; Kan Handa; Anjali Mittal; Noah Meurs; Ziwen Zhu; Frank Weinberg; Michael Salomon; Ira J Fox; Chu-Xia Deng; Deepak Nagrath; Alejandro Soto-Gutierrez
Journal:  Cell Metab       Date:  2019-08-06       Impact factor: 27.287

7.  Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells.

Authors:  Alexandros Strikoudis; Anna Cieślak; Lucas Loffredo; Ya-Wen Chen; Nina Patel; Anjali Saqi; David J Lederer; Hans-Willem Snoeck
Journal:  Cell Rep       Date:  2019-06-18       Impact factor: 9.423

8.  Single Cell Gene Expression Analysis in a 3D Microtissue Liver Model Reveals Cell Type-Specific Responses to Pro-Fibrotic TGF-β1 Stimulation.

Authors:  Catherine Jane Messner; Lmar Babrak; Gaia Titolo; Michaela Caj; Enkelejda Miho; Laura Suter-Dick
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

9.  Gene Regulatory Network Analysis and Engineering Directs Development and Vascularization of Multilineage Human Liver Organoids.

Authors:  Jeremy J Velazquez; Ryan LeGraw; Farzaneh Moghadam; Yuqi Tan; Jacquelyn Kilbourne; Joseph C Maggiore; Joshua Hislop; Silvia Liu; Davy Cats; Susana M Chuva de Sousa Lopes; Christopher Plaisier; Patrick Cahan; Samira Kiani; Mo R Ebrahimkhani
Journal:  Cell Syst       Date:  2020-12-07       Impact factor: 10.304

10.  Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury.

Authors:  Shuyong Wang; Xuan Wang; Zuolong Tan; Yuxin Su; Juan Liu; Mingyang Chang; Fang Yan; Jie Chen; Tao Chen; Chuanjiang Li; Jie Hu; Yunfang Wang
Journal:  Cell Res       Date:  2019-10-18       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.